Drug Profile
RF 1017
Latest Information Update: 17 Jan 2007
Price :
$50
*
At a glance
- Originator SuperGen
- Class Antianaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 17 Jan 2007 Discontinued - Phase-II for Anaemia in USA (unspecified route)
- 08 Jan 2001 No-Development-Reported for Anaemia in USA (Unknown route)
- 13 May 1998 Phase-II clinical trials for Anaemia in USA (Unknown route)